Wendy Yan - BeiGene Senior Vice President Head of Regulatory Affairs
| BGNE Stock | USD 144.12 5.13 3.69% |
President
Ms. Wendy Yan is Senior Vice President, Head of Regulatory Affairs of the company. since August 2014. Prior to joining us, Ms. Yan served in various positions, including Director, Head of Regulatory Affairs for China, and Global Regulatory Strategist, at Bayer HealthCare AG from 2008 to 2014. Prior to that, Ms. Yan served at GlaxoSmithKline Pharmaceutical China as both a director and Head of Regulatory Affairs. Ms. Yan also served as a Senior Regulatory Affair Manager at AstraZeneca plc. previously since 2014.
| Age | 50 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108 |
| Phone | 345 949 4123 |
| Web | https://www.beigene.com |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Christiana Stamoulis | Incyte | 47 | |
| Maria Pasquale | Incyte | 52 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Nicole Perry | Apellis Pharmaceuticals | 53 | |
| Peter Leone | Arrowhead Pharmaceuticals | 58 | |
| Henry Fuchs | Biomarin Pharmaceutical | 60 | |
| Ahmad Sadr | Apellis Pharmaceuticals | 44 | |
| Daniel Spiegelman | Biomarin Pharmaceutical | 58 | |
| David Gryska | Incyte | 61 | |
| Lukas Scheibler | Apellis Pharmaceuticals | 47 | |
| Anthony Boral | Blueprint Medicines Corp | 55 | |
| Susan Boynton | Arrowhead Pharmaceuticals | N/A | |
| Vijay Iyengar | Incyte | 45 | |
| Andrew MBA | VaxcyteInc | 56 | |
| Wade Walke | Ionis Pharmaceuticals | N/A | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Dashyant Dhanak | Incyte | 63 | |
| Richard Ranieri | Biomarin Pharmaceutical | 59 | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Thomas Lackner | Apellis Pharmaceuticals | 51 | |
| Kennett Sprogoee | Ascendis Pharma AS | 36 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, Chairman CoFounder | ||
| Howard Liang, CFO and Chief Strategy Officer | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Jason Yang, Senior Vice President Head of Clinical Development | ||
| Wang Lai, Global RD | ||
| Thomas Malley, Non-Executive Independent Director | ||
| Eric Hedrick, Interim Chief Medical Officer, Immuno-Oncology | ||
| Qingqing Yi, Director | ||
| Titus Ball, VP Officer | ||
| Julia Wang, CFO Officer | ||
| Hing Chau, Company Secretary | ||
| Daniel Maller, VP Accounting | ||
| Timothy Chen, Director | ||
| Wendy Yan, Senior Vice President Head of Regulatory Affairs | ||
| Ke Tang, Director | ||
| Xiaobin Wu, President COO | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Ranjeev Krishana, Director | ||
| Chan Lee, General VP | ||
| Donald Glazer, Director | ||
| Kevin Mannix, VP Relations | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Michael Goller, Director | ||
| JingShyh Su, Independent Director | ||
| Diana Francis, VP Compliance | ||
| Yan Qi, Senior China | ||
| Jane Huang, Chief Medical Officer, Hematology |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 186.71 B | ||||
| Shares Outstanding | 104.49 M | ||||
| Shares Owned By Insiders | 19.83 % | ||||
| Shares Owned By Institutions | 48.10 % | ||||
| Number Of Shares Shorted | 1.73 M | ||||
| Price To Earning | (16.19) X |
BeiGene Investors Sentiment
The influence of BeiGene's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BeiGene. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BeiGene's public news can be used to forecast risks associated with an investment in BeiGene. The trend in average sentiment can be used to explain how an investor holding BeiGene can time the market purely based on public headlines and social activities around BeiGene. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BeiGene's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BeiGene's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BeiGene's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BeiGene.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BeiGene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BeiGene's short interest history, or implied volatility extrapolated from BeiGene options trading.
Pair Trading with BeiGene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BeiGene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BeiGene will appreciate offsetting losses from the drop in the long position's value.Moving against BeiGene Stock
| 0.64 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.54 | ELYM | Eliem Therapeutics | PairCorr |
| 0.47 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to BeiGene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BeiGene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BeiGene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BeiGene to buy it.
The correlation of BeiGene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BeiGene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BeiGene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BeiGene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.45) | Revenue Per Share 23.554 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.22) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.